| 1 |
中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订) [J]. 中华内科杂志, 2022, 61(5): 480-487.
|
|
Chinese Hematology Association, Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision) [J]. Chinese Journal of Internal Medicine, 2022,61(5): 480-487.
|
| 2 |
CASTANEDA O, BAZ R. Multiple myeloma genomics: a concise review[J]. Acta Med Acad, 2019, 48(1): 57-67.
|
| 3 |
MOREAU P, GARFALL A L, VAN DE DONK N W C J, et al. Teclistamab in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2022, 387(6): 495-505.
|
| 4 |
MOREAU P, KUMAR S K, SAN MIGUEL J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group[J]. Lancet Oncol, 2021, 22(3): e105-e118.
|
| 5 |
USMANI S Z, QUACH H, MATEOS M V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study[J]. Lancet Oncol, 2022, 23(1): 65-76.
|
| 6 |
de WEERS M, TAI Y T, van der VEER M S, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors[J]. J Immunol, 2011, 186(3): 1840-1848.
|
| 7 |
AGARWAL R, GUPTA R, BHASKAR A, et al. Synchronous presentation of multiple myeloma and lung cancer[J]. J Clin Oncol, 2008, 26(35): 5814-5816.
|
| 8 |
KAISER M F, CROFT J, SHAH P, et al. Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment[J]. Br J Haematol, 2020, 189(1): e1-e3.
|
| 9 |
WANG Z, DENG H, ZHANG L, et al. Daratumumab for refractory IgD multiple myeloma with lung cancer and persistent thrombocytopenia: a case report [J]. Clin Lab, 2021, 67(11):2589.
|
| 10 |
DONG H H, LI J, KANG L, et al. Simultaneous multiple myeloma and non-small cell lung carcinoma: a case report and review of the literature[J]. Oncol Lett, 2022, 23(6): 195.
|
| 11 |
ZUO W, ZHU X, YANG J, et al. Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: a case report[J]. Medicine (Baltimore), 2017, 96(1): e5787.
|
| 12 |
LIN J, ZHU H, LU X, et al. Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses[J]. Intern Med, 2010, 49(21): 2341-2346.
|
| 13 |
GIBSON S J, COOPER J D, PHAM K, et al. Prognostic impact of second primary malignancies in multiple myeloma: an ASCO CancerLinQ discovery analysis of the modern era[J]. Am J Hematol, 2023, 98(11): E325-E327.
|
| 14 |
KLEBER M, IHORST G, TERHORST M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score[J]. Blood Cancer J, 2011, 1(9): e35.
|
| 15 |
ENGELHARDT M, IHORST G, LANDGREN O, et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years[J]. Haematologica, 2015, 100(10): 1340-1349.
|
| 16 |
MACLACHLAN K, DIAMOND B, MAURA F, et al. Second malignancies in multiple myeloma; emerging patterns and future directions[J]. Best Pract Res Clin Haematol, 2020, 33(1): 101144.
|
| 17 |
JONES J R, CAIRNS D A, GREGORY W M, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial[J]. Blood Cancer J, 2016, 6(12): e506.
|
| 18 |
ORMEROD A, FAUSEL C A, ABONOUR R, et al. Observations of second primary malignancy in patients with multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2012, 12(2): 113-117.
|
| 19 |
SCHRANK Z, CHHABRA G, LIN L, et al. Current molecular-targeted therapies in NSCLC and their mechanism of resistance[J]. Cancers (Basel), 2018, 10(7): E224.
|
| 20 |
EGUREN-SANTAMARIA I, SANMAMED M F, GOLDBERG S B, et al. PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice[J]. Clin Cancer Res, 2020, 26(16): 4186-4197.
|
| 21 |
PALUMBO A, AVET-LOISEAU H, OLIVA S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group[J]. J Clin Oncol, 2015, 33(26): 2863-2869.
|
), ZHOU Lingyun(
